Zymeworks Raises $100M Via Equity Issued At 14% Discount

Zymeworks Inc ZYME has priced its underwritten public offering of 9.16 million common shares, pre-funded warrants to purchase up to 3.34 million shares. 

• The shares are offered at $8.00 per common share and the pre-funded warrants at $7.9999 per pre-funded warrant. 
• The offer price represents a discount of almost 14% from the last close price of $9.32 on Wednesday.
• See the offer prospectus here.
• The gross proceeds to Zymeworks are expected to be approximately $100.0 million. 
• Underwriters have an option to purchase up to an additional 1.875 million shares.
• The Company will use the proceeds to develop zanidatamab, adaptive Phase 1 trials of ZW49, and for general corporate purposes.
• Related: Zymeworks To Cut Its Workforce By Almost 25%, Outlines 2022 & 2023 Priorities.
• The offering is expected to close by January 31.
• Price Action: ZYME shares are down 11.5% at $8.25 during the premarket session on the last check Thursday.